Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Caris Life Sciences, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-90.8% vs price
Base Case (Median)
-81.9% vs price
Bull Case (75th pct.)
-64.7% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $5.17 | -81.9% | High (40%) |
| Graham Number | $19.55 | -31.4% | Medium (40%) |
| EV/EBITDA | $1.70 | -94.0% | Medium (20%) |
| EV/FCF | $10.06 | -64.7% | Medium (20%) |
| Earnings Power Value | $2.61 | -90.9% | Medium (50%) |
Based on 5 out of 7 methods, CAI appears overvalued at the current price of $28.49. The base case fair value of $5.17 implies 81.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.